NL2030537B1 - Method for synthesizing of imidazo[1,2-a] pyridine-3-formic acid - Google Patents

Method for synthesizing of imidazo[1,2-a] pyridine-3-formic acid Download PDF

Info

Publication number
NL2030537B1
NL2030537B1 NL2030537A NL2030537A NL2030537B1 NL 2030537 B1 NL2030537 B1 NL 2030537B1 NL 2030537 A NL2030537 A NL 2030537A NL 2030537 A NL2030537 A NL 2030537A NL 2030537 B1 NL2030537 B1 NL 2030537B1
Authority
NL
Netherlands
Prior art keywords
imidazo
pyridine
formic acid
reaction
synthesizing
Prior art date
Application number
NL2030537A
Other languages
Dutch (nl)
Other versions
NL2030537A (en
Inventor
Lai Xinsheng
Zhang Xianglong
Cheng Wei
Lai Chao
Fu Huawei
Fan Hongli
Original Assignee
Shandong Youbang Biochemical Tech Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shandong Youbang Biochemical Tech Co Ltd filed Critical Shandong Youbang Biochemical Tech Co Ltd
Priority to NL2030537A priority Critical patent/NL2030537B1/en
Publication of NL2030537A publication Critical patent/NL2030537A/en
Application granted granted Critical
Publication of NL2030537B1 publication Critical patent/NL2030537B1/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

The present disclosure relates to the field of organic synthesis, and more particularly to a method for synthesizing imidazo[l,2—a] pyridine—3—formic acid. The method comprises the following steps: enabling N,N—dimethylformamide dimethylacetal to react with 2— aminopyridine at 40—100°C for 2 to 8 hours to obtain an N,N— dimethyl—N’—2—pyridinecarboxamidine intermediate, enabling the intermediate to react with ethyl bromoacetate at 50—l60°C, and carrying out recrystallization to obtain a pure product; carrying out a hydrolysis reaction on imidazo[l,2—a] pyridine—3—ethyl formate for l to 5 hours in a certain solvent, and after the reaction is completed, carrying out hydrochloric acid neutralizing, filtering, water washing and drying to directly obtain a pure product of imidazo[l,2—a] pyridine—3—formic acid. The method is easy in availableness of reaction raw materials, reasonable in price, gentle in reaction condition, easy to operate, easy to control and simple in post—treatment, and in addition, the product quality obtained is stable, and the product purity is high.

Description

P937/NLpd METHOD FOR SYNTHESIZING OF IMIDAZO[1,2-A] PYRIDINE-3-FORMIC ACID
TECHNICAL FIELD The present disclosure relates to the field of organic syn- thesis, and more particularly to a method for synthesizing imid- azo[1,2-a] pyridine-3-formic acid.
BACKGROUND ART Imidazo[l,2-a] pyridine-3-formic acid is an important inter- mediate for organic synthesis, which is mainly applied to medical intermediates, organic synthesis and organic solvents, and also applied to aspects such as dye production, pesticide production and spices. Conventional preparation of imidazo[1,2-a] pyridine-3-formic acid has the following defects: (1) A large number of byproducts are produced, resulting in a dark product color and difficulties in refining and purification. Even after multiple times of recrystallization with organic sol- vents, the quality still cannot meet high requirements, and re- peated crystallization results in a low product yield, increased cost, and tedious operations. (2) A chemical reduction method used has serious equipment corrosion and environment pollution, and thus it is restricted from development at present. (3) Raw materials are limited in source, high in price and complicated to operate. {4} A noble metal catalyst needs to be used, so that the preparation cost is increased. All above problems all need to be solved.
SUMMARY Aiming at solving defects of the prior art, the present dis- closure provides a method for synthesizing imidazo[1,2-a] pyri- dine-3-formic acid. The synthesis method is simple to operate, high in yield and applicable to laboratory and industrial produc-
tion.
The present disclosure is achieved through the following technical solution: A method for synthesizing imidazo[1,2-a] pyridine-3-formic acid, comprising the following steps: {1) preparing imidazo[1,2-a] pyridine-3-ethyl formate: ena- bling N,N-dimethylformamide dimethylacetal as both a solvent and a reaction raw material to react with 2-aminopyridine at 40-100°C for 2-8 hours to obtain an N,N-dimethyl-N’-2-pyridinecarboxamidine intermediate, enabling the intermediate which does not need to be purified to react with ethyl bromoacetate at 50-160°C for 3-15 hours in a certain solvent under the action of an alkali, after the reaction is completed, cooling to a room temperature, extract- ing with ethyl acetate, washing with water and a saline solution, drying with anhydrous sodium sulfate, carrying out rotary evapora- tion concentration to obtain a crude product of imidazo[1,2-a] pyridine-3-ethyl formate, and recrystallizing the crude product to obtain a pure product; and (2) preparing imidazo[1,2-a] pyridine-3-formic acid: under the action of the alkali, carrying out a hydrolysis reaction on the imidazo[1,2-a] pyridine-3-ethyl formate for 1-5 hours in a certain solvent, and after the reaction ends, carrying out neu- tralizing with hydrochloric acid, filtering, water washing and drying to directly obtain a pure product of imidazo[1,2-a] pyri- dine-3-formic acid.
Reactions are as follows: Oo (XL DMF-DMA Si ot N™ “NH, NZ SNASNT base solvent | AN ~_N o OH © o According to the method for synthesizing the imidazo[1,2-a] pyridine-3-formic acid in the present disclosure, the alkali in the step (1) is at least one of potassium bicarbonate, potassium carbonate, sodium bicarbonate and sodium carbonate.
According to the method for synthesizing the imidazo[1,2-a] pyridine-3-formic acid in the present disclosure, the solvent in the step (1) is at least one of dioxane, toluene and N,N- dimethylformamide.
According to the method for synthesizing the imidazo[1,2-a] pyridine-3-formic acid in the present disclosure, a mixed solution of n-hexane and ethyl acetate in a volume ratio of 1: 1 is adopted for recrystallization in the step (1).
According to the method for synthesizing the imidazo[1,2-a] pyridine-3-formic acid in the present disclosure, the molar ratio of N,N-dimethylformamide dimethylacetal to 2-aminopyridine to the alkali to ethyl bromoacetate in the step (1) is (2.5-3.5): 1: (1-
2.5): (1-2.5).
According to the method for synthesizing the imidazo[1,2-a] pyridine-3-formic acid in the present disclosure, the hydrolysis temperature in the step (2) is 20-80°C.
According to the method for synthesizing the imidazo[1,2-a] pyridine-3-formic acid in the present disclosure, , the solvent in the step (2) is a mixture of methanol or ethanol and water.
According to the method for synthesizing the imidazo[1,2-a] pyridine-3-formic acid in the present disclosure, the alkali in the step (2) is at least one of sodium hydroxide, potassium hy- droxide and lithium hydroxide.
According to the method for synthesizing the imidazo[1,2-a] pyridine-3-formic acid in the present disclosure, the concentra- tion of hydrochloric acid in the step (2) is 30%.
According to the method for synthesizing the imidazo[1,2-a] pyridine-3-formic acid in the present disclosure, the amount of the imidazo[1,2-a] pyridine-3-ethyl formate to the alkali in the step (2) is 1: (1-2.5).
The present disclosure has the beneficial effects that the method is easy in reaction raw material obtaining, reasonable in price, gentle in reaction condition, easy to operate, easy to con- trol and simple in post-treatment, and in addition, is stable in product quality and high in purity.
DETAILED DESCRIPTION OF THE EMBODIMENTS Example 1 80 mL (71.7 g) of N,N-dimethylformamide dimethylacetal as both a solvent and a reaction raw material was taken to react with 2-aminopyridine (18.8 g, 200 mmol) at 40°C for 5 hours to obtain an N,N-dimethyl-N’-2-pyridinecarboxamidine intermediate after the re- action ended. Rotary evaporation was carried out to remove exces- sive N,N-dimethylformamide dimethylacetal, 120 mL (114 g) of N,N- dimethylformamide (DMF), NaHCO; {25.2 g, 300 mmol) and ethyl bromo- acetate (50.1 g, 300 mmol) were added to react for 10 hours at 50°C. After the reaction ended, the mixture was cooled to a room temperature, and 600 mL of water and 200 mL of ethyl acetate were added for extraction. The organic phase was separated, and the aqueous phase was extracted with ethyl acetate (3*200 mL), the or- ganic phases were combined, washed with water (2*150 mL), washed with 200 mL of a saturated saline solution, dried with anhydrous Na:S0,, and filtered. The filtrate was concentrated to obtain a crude product of imidazo[1,2-a] pyridine-3-ethyl formate, and the crude product was recrystallized with a mixed solution of n-hexane and ethyl acetate in a ratio of 1: 1 (volume ratio} to obtain 30.6 g of pure product. The yield was 80.5%, the melting point was:
49.6-51.5°C, 1HNMR (400 MHz, CDCl3) &: 9.31 (d, J=6.8Hz, 1H), 8.31 (s,1H), 7.74 (d, J=9.2Hz, 1H), 7.41 (t,J= 7.2Hz, 1H), 7.05 (t,J=6.8Hz, 1H) 4.42 (gq,J=7.2Hz, 2H), 1.42 (t,J=7.2Hz, 3H).
The imidazo[1,2-a] pyridine-3-ethyl formate (19.0 g, 100 mmol) and 100 mL of methanol were added to a 250 mL single-mouth flask. Sodium hydroxide (6.0 g, 150 mmol) was dissolved to 10 mL of water, added to a reaction flask, and stirred for 2 hours at 20°C. After the reaction ended, neutralization was carried out with 30% hydrochloric acid till the pH value was 5, suction filtration was carried out, and a filter cake was washed with a small amount of water, and was dried to obtain 10.3 g of a pure product of im- idazo[1,2-a] pyridine-3-formic acid. The yield was 63.6%, and the melting point was 196-197°C, 1HNMR (400MHz, CDCl;) 3:10.88 (s, 1H),
9.33 (d, J=7.2Hz, 1H), 8.30 (s,1lH), 7.72 (d, J=9.2Hz, 1H), 7.44 (t,J=8.0Hz, 1H), 7.10 (t,J=7.2Hz, 1H).
Example 2 80 mL (71.7 g) of N,N-dimethylformamide dimethylacetal as both a solvent and a reaction raw material was taken to react with 2-aminopyridine (18.8 g, 200 mmol) at 40°C for 5 hours to obtain an 5 N,N-dimethyl-N’-2-pyridinecarboxamidine intermediate after the re- action ended. Rotary evaporation was carried out to remove exces- sive N,N-dimethylformamide dimethylacetal, 120 mL (125 g) of diox- ane, NaHCO; (20.8 g, 150 mmol) and ethyl bromoacetate (50.1 g, 300 mmol) were added to react for 10 hours at 80°C. After the reaction ended, the mixture was cooled to a room temperature, and 600 mL of water and 200 mL of ethyl acetate were added for extraction. The organic phase was separated, and the aqueous phase was extracted with ethyl acetate (3*200 mL), the organic phases were combined, washed with water (2*150 mL), washed with 200 mL of a saturated saline solution, dried with anhydrous Na:S0,, and filtered. The filtrate was concentrated to obtain a crude product of imid- azo[1,2-a] pyridine-3-ethyl formate, and the crude product was re- crystallized with a mixed solution of n-hexane and ethyl acetate in a ratio of 1: 1 (volume ratio) to obtain 21.6 g of pure prod- uct. The yield was 56.8%.
The imidazo[1,2-a] pyridine-3-ethyl formate (26.7g, 100 mmol) and 100 mL of methanol were added to a 250 mL single-mouth flask. Sodium hydroxide (8.4 g, 150 mmol) was dissolved to 10 mL of wa- ter, added to a reaction flask, and stirred for 2 hours at 40°C.
After the reaction ended, neutralization was carried out with 30% hydrochloric acid till the pH value was 4, suction filtration was carried out, and a filter cake was washed with a small amount of water, and was dried to obtain 11.1 g of a pure product of imid- azo[l,2-a] pyridine-3-formic acid. The yield was 68.6%.
Example 3 80 mL of N,N-dimethylformamide dimethylacetal as both a sol- vent and a reaction raw material was taken to react with 2- aminopyridine (18.8 g, 200 mmol) at 60°C for 5 hours to obtain an N,N-dimethyl-N’-2-pyridinecarboxamidine intermediate after the re- action ended. Rotary evaporation was carried out to remove exces- sive N,N-dimethylformamide dimethylacetal, 120 mL (103 g) of tolu-
ene, triethylamine (30.3g, 300 mmol) and ethyl bromoacetate (50.1 g, 300 mmol) were added to react for 8 hours at 100°C.
After the reaction ended, the mixture was cooled to a room temperature, and 600 mL of water and 200 mL of ethyl acetate were added for extrac- tion.
The organic phase was separated, and the aqueous phase was extracted with ethyl acetate (3*200 mL), the organic phases were combined, washed with water (2*150 mL), washed with 200 mL of a saturated saline solution, dried with anhydrous Na:S04, and fil- tered.
The filtrate was concentrated to obtain a crude product of imidazo[1,2-a] pyridine-3-ethyl formate, and the crude product was recrystallized with a mixed solution of n-hexane and ethyl acetate in a ratio of 1: 1 (volume ratio) to obtain 24.0 g of pure prod- uct.
The yield was 63.1%. The imidazo[1,2-a] pyridine-3-ethyl formate (19.0 g, 100 mmol) and 100 mL of methanol were added to a 250 mL single-mouth flask.
Sodium hydroxide (6.0 g, 150 mmol) was dissolved to 10 mL of water, added to a reaction flask, and stirred for 2 hours at 40°C.
After the reaction ended, neutralization was carried out with 30% hydrochloric acid till the pH value was 4, suction filtration was carried out, and a filter cake was washed with a small amount of water, and was dried to obtain 10.5 g of a pure product of im- idazo[1,2-a] pyridine-3-formic acid.
The yield was 65.1%. Example 4 80 mL of N,N-dimethylformamide dimethylacetal as both a sol- vent and a reaction raw material was taken to react with 2- aminopyridine (18.8 g, 200 mmol) at 60°C for 5 hours to obtain an N,N-dimethyl-N’-2-pyridinecarboxamidine intermediate after the re- action ended.
Rotary evaporation was carried out to remove exces- sive N,N-dimethylformamide dimethylacetal, 120 mL (125 g) of diox- ane, Na2c03{(15.9g, 150 mmol) and ethyl bromoacetate {50.1 g, 300 mmol) were added to react for 6 hours at 100°C.
After the reaction ended, the mixture was cooled to a room temperature, and 600 mL of water and 200 mL of ethyl acetate were added for extraction.
The organic phase was separated, and the aqueous phase was extracted with ethyl acetate (3*200 mL), the organic phases were combined, washed with water (2*150 mL), washed with 200 mL of a saturated saline solution, dried with anhydrous Na:S0,4, and filtered. The filtrate was concentrated to obtain a crude product of imid- azo[l,2-a] pyridine-3-ethyl formate, and the crude product was re- crystallized with a mixed solution of n-hexane and ethyl acetate in a ratio of 1: 1 (volume ratio) to obtain 26.1 g of pure prod- uct. The yield was 68.7%.
The imidazo[1,2-a] pyridine-3-ethyl formate (19.0 g, 100 mmol) and 100 mL of methanol were added to a 250 mL single-mouth flask. Sodium hydroxide (3.6 g, 150 mmol) was dissolved to 10 mL of water, added to a reaction flask, and stirred for 2 hours at 20°C. After the reaction ended, neutralization was carried out with 30% hydrochloric acid till the pH value was 5, suction filtration was carried out, and a filter cake was washed with a small amount of water, and was dried to obtain 11.2 g of a pure product of im- idazo[l,2-a] pyridine-3-formic acid. The yield was 69.0%.
Example 5 69 mL of N,N-dimethylformamide dimethylacetal as both a sol- vent and a reaction raw material was taken to react with 2- aminopyridine (18.8 g, 200 mmol) at 40°C for 8 hours to obtain an N,N-dimethyl-N’-2-pyridinecarboxamidine intermediate after the re- action ended. Rotary evaporation was carried out to remove exces- sive N,N-dimethylformamide dimethylacetal, 120 mL (62 g) of diox- ane, 60 mL (52 g) toluene, NaZC03(5.3 g, 50 mmol). K2C03(13.9 9, 100 mmol), KHCO3{(5 g, 50 mmol) and ethyl bromoacetate (33.4g, 200 mmol) were added to react for 15 hours at 60°C. After the reaction ended, the mixture was cooled to a room temperature, and 600 mL of water and 200 mL of ethyl acetate were added for extraction. The organic phase was separated, and the aqueous phase was extracted with ethyl acetate (3*200 mL), the organic phases were combined, washed with water (2*150 mL), washed with 200 mL of a saturated saline solution, dried with anhydrous Na,S0,, and filtered. The filtrate was concentrated to obtain a crude product of imid- azo[1,2-a] pyridine-3-ethyl formate, and the crude product was re- crystallized with a mixed solution of n-hexane and ethyl acetate in a ratio of 1: 1 (volume ratio) to obtain 25.5 g of pure prod- uct. The yield was 67.1%.
The imidazo[1,2-a] pyridine-3-ethyl formate (19.0 g, 100 mmol) and 100 mL of methanol were added to a 250 mL single-mouth flask. Lithium hydroxide (1.2g, 50 mmol), sodium hydroxide (2g, 50 mmol) were dissolved to 10 mL of water, added to a reaction flask, and stirred for 1 hour at 80°C. After the reaction ended, neutrali- zation was carried out with 30% hydrochloric acid till the pH val- ue was 5, suction filtration was carried out, and a filter cake was washed with a small amount of water, and was dried to obtain
11.1 g of a pure product of imidazo[1,2-a] pyridine-3-formic acid. The yield was 68.4%. Example 6 97 mL of N,N-dimethylformamide dimethylacetal as both a sol- vent and a reaction raw material was taken to react with 2- aminopyridine (18.8 g, 200 mmol) at 100°C for 2 hours to obtain an N,N-dimethyl-N’-2-pyridinecarboxamidine intermediate after the re- action ended. Rotary evaporation was carried out to remove exces- sive N,N-dimethylformamide dimethylacetal, 20 mL (19 g) of N,N- dimethylformamide (DMF), 60 mL (é2g) of dioxane, 60 mL (52g) of toluene, Na2co3 (21.2g, 200 mmol), K2C03 (13.99, 100 mmol), KHCO3 ( 20 g, 200 mmol) and ethyl bromoacetate (83.59, 500 mmol) were added to react for 3 hours at 160°C. After the reaction ended, the mixture was cooled to a room temperature, and 600 mL of water and 200 mL of ethyl acetate were added for extraction. The organic phase was separated, and the aqueous phase was extracted with ethyl acetate (3*200 mL), the organic phases were combined, washed with water (2*150 mL), washed with 200 mL of a saturated saline solution, dried with anhydrous Na,30;, and filtered. The filtrate was concentrated to obtain a crude product of imidazo[1,2-a] pyri- dine-3-ethyl formate, and the crude product was recrystallized with a mixed solution of n-hexane and ethyl acetate in a ratio of 1: 1 (volume ratio) to obtain 26.4 g of pure product. The yield was 69.4%. The imidazo[1,2-a] pyridine-3-ethyl formate (19.0 g, 100 mmol) and 140 mL of methanol were added to a 250 mL single-mouth flask. Lithium hydroxide (4.8 g, 200 mmol), sodium hydroxide (2g, 50 mmol) were dissolved to 20 mL of water, added to a reaction flask, and stirred for 5 hours at 20°C.
After the reaction ended, neutralization was carried out with 30% hydrochloric acid till the pH value was 5, suction filtration was carried out, and a filter cake was washed with a small amount of water, and was dried to ob- tain 11.3 g of a pure product of imidazo[1,2-a] pyridine-3-formic acid.
The yield was ©9.5%.

Claims (5)

CONCLUSIESCONCLUSIONS 1. Werkwijze voor het synthetiseren van imidazo[1,2-alpyridine-3- mierenzuur, welke werkwijze de volgende stappen omvat: (1) bereiding van imidazo[1,2-a]pyridine-3-ethylformiaat: N,N- dimethylformamidedimethylacetaal als zowel oplosmiddel als reac- tiegrondstof wordt in staat gesteld te reageren met 2- aminopyridine bij 40 - 100 °C gedurende 2 — 8 uur om een N,N- dimethyl-N'-2-pyridylformamidine als tussenproduct te verkrijgen, waardoor het tussenproduct, dat niet hoeft te worden gezuiverd, 3 - 15 uur kan reageren met ethylbroomacetaat bij 50 - 160 °C in een bepaald oplosmiddel onder de inwerking van een alkali, nadat de reactie is voltooid, afkoelen tot kamertemperatuur, extraheren met ethylacetaat, wassen met water en een zoutoplossing, drogen met watervrij natriumsulfaat, het uitvoeren van rotatieverdampingscon- centratie om een ruw product van imidazo[1,2-a]pyridine-3- ethylformiaat te verkrijgen, en het herkristalliseren van het ruwe product om een zuiver product te verkrijgen; en (2) bereiding van imidazo[1,2-a]pyridine-3-mierenzuur: onder in- werking van de alkali, een hydrolysereactie uitvoeren op het imi- dazo[1,;2-alpyridine-3-ethylformiaat voor 1 - 5 uur in een bepaald oplosmiddel, en nadat de reactie is afgelopen, neutraliseren met zoutzuur, filtreren, wassen met water en drogen om direct een zui- ver product van imidazo[1,2-a]pyridine-3-mierenzuur te verkrijgen.A method for synthesizing imidazo[1,2-alpyridine-3-formic acid, which method comprises the following steps: (1) preparation of imidazo[1,2-a]pyridine-3-ethylformate: N,N-dimethylformamide dimethylacetal as both solvent and reaction raw material is allowed to react with 2-aminopyridine at 40-100°C for 2-8 hours to obtain an intermediate N,N-dimethyl-N'-2-pyridylformamidine, thereby making the intermediate , which does not need to be purified, can react with ethyl bromoacetate at 50 - 160 °C for 3 - 15 hours in a certain solvent under the action of an alkali, after the reaction is completed, cool to room temperature, extract with ethyl acetate, wash with water and brine, drying with anhydrous sodium sulfate, conducting rotary evaporation concentration to obtain a crude product of imidazo[1,2-a]pyridine-3-ethylformate, and recrystallizing the crude product to obtain a pure product; and (2) preparation of imidazo[1,2-a]pyridine-3-formic acid: under the action of the alkali, perform a hydrolysis reaction on the imidazo[1,;2-a]pyridine-3-ethyl formate for 1- 5 hours in a certain solvent, and after the reaction is over, neutralize with hydrochloric acid, filter, wash with water and dry to directly obtain a pure product of imidazo[1,2-a]pyridine-3-formic acid. 2. Werkwijze voor het synthetiseren van imidazo[1,2-a]pyridine-3- mierenzuur volgens conclusie 1, waarbij in stap (1) een gemengde oplossing van n-hexaan en ethylacetaat in een volumeverhouding van 1:1 wordt aangenomen voor herkristallisatie.The method for synthesizing imidazo[1,2-a]pyridine-3-formic acid according to claim 1, wherein in step (1) a mixed solution of n-hexane and ethyl acetate in a volume ratio of 1:1 is adopted for recrystallization . 3. Werkwijze voor het synthetiseren van imidazo[1,2-a]pyridine-3- mierenzuur volgens conclusie 1, waarbij in stap (1) de molaire verhouding van N,N-dimethylformamide dimethylacetaal tot de 2- aminopyridine tot het alkali tot ethylbroomacetaat is (2,5-3,5) : 1: (1-2,5) : (1-2,5).The method for synthesizing imidazo[1,2-a]pyridine-3-formic acid according to claim 1, wherein in step (1), the molar ratio of N,N-dimethylformamide dimethylacetal to the 2-aminopyridine to the alkali to ethyl bromoacetate is (2.5-3.5) : 1 : (1-2.5) : (1-2.5). 4. Werkwijze voor het synthetiseren van imidazo[1,2-alpyridine-3- mierenzuur volgens conclusie 1, waarbij in stap (2) de alkali ten minste één van natriumhydroxide, kaliumhydroxide en lithiumhy- droxide is.The method for synthesizing imidazo[1,2-alpyridine-3-formic acid according to claim 1, wherein in step (2), the alkali is at least one of sodium hydroxide, potassium hydroxide and lithium hydroxide. 5. Werkwijze voor het synthetiseren van imidazo[1,2-a]pyridine-3- mierenzuur volgens conclusie 1, waarbij in stap (2) de hoeveelheid imidazo[1,2-a]pyridine-3-ethylformiaat tot de alkali 1 : (1-2,5) is.The method for synthesizing imidazo[1,2-a]pyridine-3-ethyl formate according to claim 1, wherein in step (2), the amount of imidazo[1,2-a]pyridine-3-ethyl formate to the alkali is 1: (1-2.5).
NL2030537A 2022-01-13 2022-01-13 Method for synthesizing of imidazo[1,2-a] pyridine-3-formic acid NL2030537B1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
NL2030537A NL2030537B1 (en) 2022-01-13 2022-01-13 Method for synthesizing of imidazo[1,2-a] pyridine-3-formic acid

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
NL2030537A NL2030537B1 (en) 2022-01-13 2022-01-13 Method for synthesizing of imidazo[1,2-a] pyridine-3-formic acid

Publications (2)

Publication Number Publication Date
NL2030537A NL2030537A (en) 2022-11-15
NL2030537B1 true NL2030537B1 (en) 2022-11-30

Family

ID=84046038

Family Applications (1)

Application Number Title Priority Date Filing Date
NL2030537A NL2030537B1 (en) 2022-01-13 2022-01-13 Method for synthesizing of imidazo[1,2-a] pyridine-3-formic acid

Country Status (1)

Country Link
NL (1) NL2030537B1 (en)

Also Published As

Publication number Publication date
NL2030537A (en) 2022-11-15

Similar Documents

Publication Publication Date Title
CN109956870A (en) A kind of Luo Shasi his synthetic method and its midbody compound
CN114805314B (en) Synthesis method of Entecavir
NL2030537B1 (en) Method for synthesizing of imidazo[1,2-a] pyridine-3-formic acid
CN116283629B (en) Preparation method of 5-amino-2-nitrobenzoic acid
CN106045995B (en) A kind of synthetic method of 5 bromine 1H pyrrolo-es [2,3 b] pyridines
CN104016954A (en) Method for preparing and purifying nebivolol intermediate
CN108299466B (en) Improved dolutegravir synthesis method
SU554816A3 (en) The method of obtaining nitrogen-containing polycyclic compounds or their salts, or racemates, or optical antipodes
CN112479993A (en) Synthetic method applied to KRAS inhibitor drug heterocyclic intermediate
CN111747879A (en) Large-process synthesis method of erexib
CN103864786A (en) Method for synthesizing 6-fluoroimidazo-[1,2-a]-pyridine-3-formic acid
CN113773235B (en) Synthesis method of clorsulon
CN103965192A (en) Synthesis method of 6-chloroimidazo[1,2-alpha]pyridyl-3-formic acid
CN114163362B (en) Preparation method of N-benzenesulfonyl-4-halo-2-nitroaniline
CN111039838B (en) Preparation method of 3-acetylmercapto-2-methylpropanoic acid
CN110041285B (en) Preparation method of 2, 4, 5-trisubstituted oxazole compound
CN114213261A (en) Preparation method of 4-methoxy-2-nitroaniline
CN109081826B (en) Preparation method of oxidant IBX
MX2007007923A (en) PROCESS FOR PREPARING 5,6-DIHYDRO-4-(S)-(ETHYLAMINO)-6-(S) METHYL-4H-THIENO[2,3b]THIOPYRAN-2-SULPHONAMIDE-7,7-DIOXIDE HCI.
CN116969849A (en) Preparation method of deuterated o-aminophenol and intermediate thereof
CN111533699A (en) Synthetic method of 2- (trifluoromethyl) pyrimidine-5-ol
CN115819303A (en) Preparation method of compound 3-fluoro-4-isothiocyanato-2-trifluoromethyl benzonitrile
CN116239558A (en) Preparation method of eriodictyol
JP2022533485A (en) Process for preparing salicylamine acetate
CN115650895A (en) Simple synthesis method of 3, 3-dimethylpyrrolidin-2-one

Legal Events

Date Code Title Description
PD Change of ownership

Owner name: SHAANXI YOUBANG BIOPHARMA TECHNOLOGY CO., LTD.; CN

Free format text: DETAILS ASSIGNMENT: CHANGE OF OWNER(S), ASSIGNMENT; FORMER OWNER NAME: SHANDONG YOUBANG BIOCHEMICAL TECHNOLOGY CO., LTD.

Effective date: 20231003